Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Artur J. Jurczyszyn"'
Autor:
Hélène Demarquette, Stéphanie Guidez, Artur J. Jurczyszyn, Denis Caillot, Brigitte Pegourie, Marie Lorraine Chretien, Charles Lancesseur, Lionel Karlin, Cristina M. Joao, Claire Bories, Laurence Legros, Laurent Garderet, Souhila Ikhlef, Martine Escoffre, Bruno Royer, Laurent Voillat, Cyrille Hulin, Anne Banos, Eric G. Voog, Anne-Marie Stoppa, Lofti Benboubker, Niels Abildgaard, Katell Le Du, Philippe Moreau, Thierry Facon, Sonja Zweegman, Margaret MACRO, Francesca Gay, Evangelos Terpos, Xavier Leleu
Publikováno v:
Demarquette, H, Guider, S, Jurczyszyn, A J, Caillot, D, Pegourie, B, Chretien, M L, Lancesseur, C, Karlin, L, Joao, C M, Bories, C, Legros, L, Garderet, L, Ikhlef, S, Escoffre, M, Royer, B, Voillat, L, Hulin, C, Banos, A, Voog, E G, Stoppa, A-M, Benbouhker, L, Abildgaard, N, Le Du, K, Moreau, P, Facon, T, Zweegman, S, Macro, M, Gay, F, Terpos, E & Leleu, X 2015, ' Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide ', Blood, vol. 126, no. 23 . < http://www.mendeley.com/research/time-spare-newly-diagnosed-non-transplant-eligible-myeloma-endmm-thalidomide >
Demarquette, H, Guidez, S, Jurczyszyn, A J, Caillot, D, Pegourie, B, Chretien, M L, Lancesseur, C, Karlin, L, Joao, C M, Bories, C, Legros, L, Garderet, L, Ikhlef, S, Escoffre, M, Royer, B, Voillat, L, Hulin, C, Banos, A, Voog, E G, Stoppa, A M, Benboubker, L, Abildgaard, N, Du, K L, Moreau, P, Facon, T, Zweegman, S, Macro, M, Gay, F, Terpos, E & Leleu, X 2015, ' Time to spare newly diagnosed non transplant eligible myeloma (ENDMM) from thalidomide ', Blood, vol. 126, no. 23, pp. 4245 . < http://www.bloodjournal.org/content/126/23/4245.article-info >
Blood, 126(23). American Society of Hematology
Demarquette, H, Guidez, S, Jurczyszyn, A J, Caillot, D, Pegourie, B, Chretien, M L, Lancesseur, C, Karlin, L, Joao, C M, Bories, C, Legros, L, Garderet, L, Ikhlef, S, Escoffre, M, Royer, B, Voillat, L, Hulin, C, Banos, A, Voog, E G, Stoppa, A M, Benboubker, L, Abildgaard, N, Du, K L, Moreau, P, Facon, T, Zweegman, S, Macro, M, Gay, F, Terpos, E & Leleu, X 2015, ' Time to spare newly diagnosed non transplant eligible myeloma (ENDMM) from thalidomide ', Blood, vol. 126, no. 23, pp. 4245 . < http://www.bloodjournal.org/content/126/23/4245.article-info >
Blood, 126(23). American Society of Hematology
Background. Thalidomide is one of the most prescribed regimens upfront in eNDMM, e.g. elderly myeloma, essentially as melphalan-prednisone-Thalidomide (MPT). Several options are offered at 1st and 2nd relapse to patients initially exposed to Thalidom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b40f86731986c0953ea06572a69905
https://research.vumc.nl/en/publications/19389c83-b49b-4c56-bca4-30a524666eca
https://research.vumc.nl/en/publications/19389c83-b49b-4c56-bca4-30a524666eca
Autor:
Charles Herbaux, Cristina M. Joao, Alexia Plocque, Valentine Richez, Francesca Gay, Loic Renaud, Laurence Legros, Laurent Garderet, Souhila Ikhlef, Brigitte Pegourie, Martine Escoffre-Barbe, Bruno Royer, Laurent Voillat, Cyrille Hulin, Anne Banos, Eric G. Voog, Lionel Karlin, Anne-Marie Stoppa, Lotfi Benboubker, Sonja Zweegman, Eva De Jongh, Niels Abildgaard, Katell Le Dû, Artur J. Jurczyszyn, Philippe Moreau, Thierry Facon, Denis Caillot, Evangelos Terpos, Xavier Leleu
Publikováno v:
Blood. 124:3481-3481
Background. Bortezomib-melphalan-prednisone (VMP) is a standard of care upfront in Multiple Myeloma (MM) ineligible for transplantation, where bortezomib was given twice weekly intra veinously. Based on the VISTA study, the median TTP was 24.0 months
Autor:
Denis Caillot, Muriel Newingerm, Margaret Macro, Brigitte Pegourie, Lionel Karlin, Francesca Gay, Claire Bories, Laurence Legros, Laurent Garderet, Souhila Ikhlef, Martine Escoffre-Barbe, Bruno Royer, Laurent Voillat, Cyrille Hulin, Anne Banos, Eric G. Voog, Anne-Marie Stoppa, Lotfi Benboubker, Eva De Jongh, Sonja Zweegman, Niels Abildgaard, Katell Le Dû, Artur J. Jurczyszyn, Philippe Moreau, Thierry Facon, Evangelos Terpos, Xavier Leleu, Catherine Vieira Dos Santos, Helene Demarquette
Publikováno v:
Blood. 124:5702-5702
Background. Thalidomide is one of the most prescribed regimens upfront in eNDMM, e.g. elderly myeloma, essentially as melphalan-prednisone-Thalidomide (MPT). Several options are offered at 1 st and 2 nd relapse to patients initially exposed to Thalid